title: The role for interleukin-12 therapy of cutaneous T cell lymphoma.
abstract: Recent phase I and phase II trials using recombinant human interleukin-12 (rhIL-12) for cutaneous T cell lymphoma (CTCL) have been completed. Observations on 32 evaluable patients revealed an overall response rate approaching 50 percent. Biopsy of regressing lesions revealed an increase in numbers of CD8+ and/or TIA-1+ T cells. These results suggest that rhIL-12 may induce lesion regression by augmenting antitumor cytotoxic T cell responses. Future trials will be focused on strategies for further immune enhancement by the concomitant use of additional immune augmenting cytokines with rhIL-12.
authors.affiliation: Department of Dermatology, University of Pennsylvania, Philadelphia 19104, USA. arook@mail.med.upenn.edu
authors.forename: A H
authors.initials: AH
authors.lastname: Rook
authors.forename: M H
authors.initials: MH
authors.lastname: Zaki
authors.forename: M
authors.initials: M
authors.lastname: Wysocka
authors.forename: G S
authors.initials: GS
authors.lastname: Wood
authors.forename: M
authors.initials: M
authors.lastname: Duvic
authors.forename: L C
authors.initials: LC
authors.lastname: Showe
authors.forename: F
authors.initials: F
authors.lastname: Foss
authors.forename: M
authors.initials: M
authors.lastname: Shapiro
authors.forename: T M
authors.initials: TM
authors.lastname: Kuzel
authors.forename: E A
authors.initials: EA
authors.lastname: Olsen
authors.forename: E C
authors.initials: EC
authors.lastname: Vonderheid
authors.forename: R
authors.initials: R
authors.lastname: Laliberte
authors.forename: M L
authors.initials: ML
authors.lastname: Sherman
mesh_terms: D000945:Antigens, Differentiation, T-Lymphocyte / Q000032:analysis / Q000276:immunology; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007150:Immunohistochemistry; D018664:Interleukin-12 / Q000009:adverse effects / Q000627:therapeutic use*; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy* / Q000276:immunology; D011994:Recombinant Proteins / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000276:immunology; D016176:T-Lymphocyte Subsets / Q000145:classification; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D016896:Treatment Outcome
chemical_list: D000945:Antigens, Differentiation, T-Lymphocyte; D000970:Antineoplastic Agents; D011994:Recombinant Proteins; D018664:Interleukin-12